An Updated Systematic Literature Review of the Economic Costs of Loneliness and Social Isolation and the Cost Effectiveness of Interventions.

IF 4.4 3区 医学 Q1 ECONOMICS
Lidia Engel, Muhammad Fikru Rizal, Sharon Clifford, Jan Faller, Michelle H Lim, Long Khanh-Dao Le, Mary Lou Chatterton, Cathrine Mihalopoulos
{"title":"An Updated Systematic Literature Review of the Economic Costs of Loneliness and Social Isolation and the Cost Effectiveness of Interventions.","authors":"Lidia Engel, Muhammad Fikru Rizal, Sharon Clifford, Jan Faller, Michelle H Lim, Long Khanh-Dao Le, Mary Lou Chatterton, Cathrine Mihalopoulos","doi":"10.1007/s40273-025-01516-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>There has been growing interest in understanding the economic impacts of loneliness and social isolation. This study updates a previous review on the economic costs of loneliness and social isolation and the cost effectiveness of related interventions.</p><p><strong>Methods: </strong>We conducted a systematic search in the MEDLINE, PsycInfo, CINAHL, and Embase databases from 2018 to 13 August 2024, supplemented by a search of the grey literature. Studies included cost-of-illness studies, economic evaluations, and social return on investment (SROI) analyses published in the English language. All studies were evaluated for quality and summarised using a narrative approach. Costs reported were converted into US$, year 2024 values.</p><p><strong>Results: </strong>In total, 15 studies were included: six cost-of-illness studies, four economic evaluations, and five SROI studies. Cost-of-illness studies primarily examined healthcare and productivity costs. All but one study reported excess costs linked to loneliness and social isolation, ranging from US$2 billion to US$25.2 billion per annum. Among four economic evaluations, three were model-based cost-utility or cost-effectiveness analyses (targeting older adults and the general population), and one was trial based (focusing on low-income individuals with health issues). One study found an intervention cost effective, whereas cost-effectiveness probabilities in others ranged from 54% to 68%. One study concluded that an intervention to reduce severe loneliness in older adults was cost effective but unlikely to be cost saving. All SROI studies reported positive returns, with SROI ratios ranging from US$2.28 to US$13.72.</p><p><strong>Conclusion: </strong>This review highlights additional evidence on the economic burden of loneliness and social isolation. Future research should explore broader cost impacts beyond healthcare and expand cost-effectiveness studies to younger populations.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40273-025-01516-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: There has been growing interest in understanding the economic impacts of loneliness and social isolation. This study updates a previous review on the economic costs of loneliness and social isolation and the cost effectiveness of related interventions.

Methods: We conducted a systematic search in the MEDLINE, PsycInfo, CINAHL, and Embase databases from 2018 to 13 August 2024, supplemented by a search of the grey literature. Studies included cost-of-illness studies, economic evaluations, and social return on investment (SROI) analyses published in the English language. All studies were evaluated for quality and summarised using a narrative approach. Costs reported were converted into US$, year 2024 values.

Results: In total, 15 studies were included: six cost-of-illness studies, four economic evaluations, and five SROI studies. Cost-of-illness studies primarily examined healthcare and productivity costs. All but one study reported excess costs linked to loneliness and social isolation, ranging from US$2 billion to US$25.2 billion per annum. Among four economic evaluations, three were model-based cost-utility or cost-effectiveness analyses (targeting older adults and the general population), and one was trial based (focusing on low-income individuals with health issues). One study found an intervention cost effective, whereas cost-effectiveness probabilities in others ranged from 54% to 68%. One study concluded that an intervention to reduce severe loneliness in older adults was cost effective but unlikely to be cost saving. All SROI studies reported positive returns, with SROI ratios ranging from US$2.28 to US$13.72.

Conclusion: This review highlights additional evidence on the economic burden of loneliness and social isolation. Future research should explore broader cost impacts beyond healthcare and expand cost-effectiveness studies to younger populations.

孤独和社会隔离的经济成本和干预措施的成本效益的最新系统文献综述。
目的:人们对了解孤独和社会隔离的经济影响越来越感兴趣。这项研究更新了先前关于孤独和社会隔离的经济成本以及相关干预措施的成本效益的综述。方法:系统检索2018年至2024年8月13日的MEDLINE、PsycInfo、CINAHL和Embase数据库,并辅以灰色文献检索。研究包括以英语发表的疾病成本研究、经济评估和社会投资回报(SROI)分析。对所有研究的质量进行评估,并采用叙述方法进行总结。报告的成本已转换为2024年的美元价值。结果:共纳入15项研究:6项疾病成本研究、4项经济评估和5项SROI研究。疾病成本研究主要考察医疗保健和生产力成本。除了一项研究外,所有研究都报告了与孤独和社会隔离有关的额外费用,每年从20亿美元到252亿美元不等。在四项经济评估中,三项是基于模型的成本效用或成本效益分析(针对老年人和一般人群),一项是基于试验的(重点关注有健康问题的低收入个人)。一项研究发现干预措施具有成本效益,而其他研究的成本效益概率从54%到68%不等。一项研究得出结论,减少老年人严重孤独感的干预措施具有成本效益,但不太可能节省成本。所有的SROI研究都报告了正回报,SROI比率从2.28美元到13.72美元不等。结论:本综述强调了关于孤独和社会孤立的经济负担的额外证据。未来的研究应该探索医疗保健之外更广泛的成本影响,并将成本效益研究扩展到更年轻的人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PharmacoEconomics
PharmacoEconomics 医学-药学
CiteScore
8.10
自引率
9.10%
发文量
85
审稿时长
6-12 weeks
期刊介绍: PharmacoEconomics is the benchmark journal for peer-reviewed, authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes. An invaluable source of applied pharmacoeconomic original research and educational material for the healthcare decision maker. PharmacoEconomics is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization. PharmacoEconomics offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信